Results for &quot;&quot;Ribosome Inactivating Proteins, Type 2&quot;&quot;[mesh_terms]

Sequence, Structure, and Binding Site Analysis of Kirkiin in Comparison with Ricin and Other Type 2 RIPs.

Stefania Maiello, Rosario Iglesias, Letizia Polito, Lucía Citores, Massimo Bortolotti, José M Ferreras, Andrea Bolognesi

Toxins 2022;13(12):862

Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.

H Stauder, E D Kreuser

Onkologie 2003;25(4):374-80

Kirkiin: A New Toxic Type 2 Ribosome-Inactivating Protein from the Caudex of .

Massimo Bortolotti, Stefania Maiello, José M Ferreras, Rosario Iglesias, Letizia Polito, Andrea Bolognesi

Toxins 2021;13(2):

In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.

R Klein, K Classen, P A Berg, R Lüdtke, M Werner, R Huber

European journal of medical research 2002;7(4):155-63

Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.

P Schöffski, I Breidenbach, J Krauter, O Bolte, M Stadler, A Ganser, K Wilhelm-Ogunbiyi, H Lentzen

European journal of cancer (Oxford, England : 1990) 2005;41(10):1431-8

Crystal structures of the free and sterol-bound forms of beta-cinnamomin.

Maria Luisa Rodrigues, Margarida Archer, Paulo Martel, Sandra Miranda, Mónica Thomaz, Francisco Javier Enguita, Ricardo P Baptista, Eduardo Pinho e Melo, Nelson Sousa, Alfredo Cravador, Maria Arménia Carrondo

Biochimica et biophysica acta 2006;1764(1):110-21

Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.

K Schumacher, B Schneider, G Reich, T Stiefel, G Stoll, P R Bock, J Hanisch, J Beuth

Anticancer research 2004;23(6D):5081-7

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).

Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, Denis Lacombe, Manfred Herold, Takuhiro Yamaguchi, Karin Wilhelm-Ogunbiyi, Hans Lentzen, Heinz Zwierzina

European journal of cancer (Oxford, England : 1990) 2008;44(12):1657-62

Mistletoe or not mistletoe is still the question.

G Büschel, H Kiene, M Hornebar

Forschende Komplementarmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine 2002;8(5):309-12

Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.

Roman Huber, Reinhild Klein, Peter A Berg, Rainer Lüdtke, Michael Werner

Journal of alternative and complementary medicine (New York, N.Y.) 2003;8(6):857-66

Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.

Peter J Goebell, Thomas Otto, Julia Suhr, Herbert Rübben

The Journal of urology 2002;168(1):72-5

Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.

B K Piao, Y X Wang, G R Xie, U Mansmann, H Matthes, J Beuth, H S Lin

Anticancer research 2004;24(1):303-9

Binding and intracellular routing of the plant-toxic lectins, lanceolin and stenodactylin.

Maria Giulia Battelli, Vittoria Scicchitano, Letizia Polito, Valentina Farini, Luigi Barbieri, Andrea Bolognesi

Biochimica et biophysica acta 2011;1800(12):1276-82

Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire.

Inge Kirchberger, Dieter Wetzel, Thomas Finger

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2004;13(2):463-79